MX2016011045A - Terapia de combinacion para cancer. - Google Patents
Terapia de combinacion para cancer.Info
- Publication number
- MX2016011045A MX2016011045A MX2016011045A MX2016011045A MX2016011045A MX 2016011045 A MX2016011045 A MX 2016011045A MX 2016011045 A MX2016011045 A MX 2016011045A MX 2016011045 A MX2016011045 A MX 2016011045A MX 2016011045 A MX2016011045 A MX 2016011045A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- combination therapy
- fluoro
- treating
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a la preparación de medicamentos para uso en el tratamiento y métodos para tratar cáncer de pulmón de células no pequeñas en un paciente que comprende [5-(4-etil-piperazin-1-ilmetil)-piridin-2-il]-[5-fluoro-4-(7-fluo ro-3-isopropil-2-metil-3H-benzoimidazol-5-il)-pirimidin-2-il]-ami na, o una sal de la misma farmacéuticamente aceptable, en combinación, como se describe, además, con un anticuerpo anti-VEGFR2, preferiblemente, ramucirumab.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461944811P | 2014-02-26 | 2014-02-26 | |
PCT/US2015/016529 WO2015130540A1 (en) | 2014-02-26 | 2015-02-19 | Combination therapy for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016011045A true MX2016011045A (es) | 2016-10-28 |
Family
ID=52630493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016011045A MX2016011045A (es) | 2014-02-26 | 2015-02-19 | Terapia de combinacion para cancer. |
Country Status (18)
Country | Link |
---|---|
US (1) | US10238656B2 (es) |
EP (1) | EP3110444B1 (es) |
JP (1) | JP5948525B1 (es) |
KR (1) | KR20160111001A (es) |
CN (1) | CN106029097A (es) |
AP (1) | AP2016009402A0 (es) |
AU (1) | AU2015223359B2 (es) |
BR (1) | BR112016016880A2 (es) |
CA (1) | CA2936558A1 (es) |
EA (1) | EA201691385A1 (es) |
ES (1) | ES2659424T3 (es) |
IL (1) | IL246761A0 (es) |
MA (1) | MA39294B1 (es) |
MX (1) | MX2016011045A (es) |
MY (1) | MY176219A (es) |
SG (1) | SG11201606958YA (es) |
TW (1) | TWI558399B (es) |
WO (1) | WO2015130540A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201625304A (zh) * | 2014-10-24 | 2016-07-16 | 美國禮來大藥廠 | 泌尿上皮癌之療法 |
EP3442572A1 (en) * | 2016-04-15 | 2019-02-20 | Eli Lilly and Company | Combination therapy of ramucirumab and abemaciclib for use in treatment of mantle cell lymphoma |
US10626107B2 (en) * | 2016-09-09 | 2020-04-21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor |
CN109952315A (zh) * | 2016-11-16 | 2019-06-28 | 伊莱利利公司 | 用于转移性结直肠癌的治疗 |
CN112119073A (zh) | 2018-04-05 | 2020-12-22 | 庄信万丰股份有限公司 | 阿贝西尼的固态形式、其用途和制备 |
JP2021517583A (ja) * | 2018-04-06 | 2021-07-26 | イーライ リリー アンド カンパニー | 小児患者における癌の治療のためのラムシルマブ |
CN113840608B (zh) * | 2019-05-30 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | Cdk4/6抑制剂与vegfr抑制剂联合在制备***的药物中的用途 |
WO2021030843A1 (en) * | 2019-08-13 | 2021-02-18 | Johnson Matthey Public Limited Company | Solid-state forms of abemaciclib, their use and preparation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
ATE510561T1 (de) | 2002-03-04 | 2011-06-15 | Imclone Llc | Kdr-spezifische menschliche antikörper und ihre verwendung |
CA2481657A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
PA8852901A1 (es) * | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
UY33226A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
-
2015
- 2015-02-13 TW TW104105148A patent/TWI558399B/zh not_active IP Right Cessation
- 2015-02-19 MY MYPI2016703120A patent/MY176219A/en unknown
- 2015-02-19 EA EA201691385A patent/EA201691385A1/ru unknown
- 2015-02-19 MX MX2016011045A patent/MX2016011045A/es unknown
- 2015-02-19 BR BR112016016880A patent/BR112016016880A2/pt not_active Application Discontinuation
- 2015-02-19 KR KR1020167022971A patent/KR20160111001A/ko active Search and Examination
- 2015-02-19 SG SG11201606958YA patent/SG11201606958YA/en unknown
- 2015-02-19 WO PCT/US2015/016529 patent/WO2015130540A1/en active Application Filing
- 2015-02-19 CA CA2936558A patent/CA2936558A1/en not_active Abandoned
- 2015-02-19 CN CN201580010432.3A patent/CN106029097A/zh active Pending
- 2015-02-19 AU AU2015223359A patent/AU2015223359B2/en not_active Expired - Fee Related
- 2015-02-19 AP AP2016009402A patent/AP2016009402A0/en unknown
- 2015-02-19 JP JP2016505628A patent/JP5948525B1/ja not_active Expired - Fee Related
- 2015-02-19 EP EP15708638.0A patent/EP3110444B1/en active Active
- 2015-02-19 US US15/115,995 patent/US10238656B2/en not_active Expired - Fee Related
- 2015-02-19 ES ES15708638.0T patent/ES2659424T3/es active Active
- 2015-02-19 MA MA39294A patent/MA39294B1/fr unknown
-
2016
- 2016-07-13 IL IL246761A patent/IL246761A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA39294B1 (fr) | 2018-12-31 |
MY176219A (en) | 2020-07-24 |
MA39294A1 (fr) | 2018-06-29 |
JP5948525B1 (ja) | 2016-07-06 |
AU2015223359B2 (en) | 2017-06-01 |
CN106029097A (zh) | 2016-10-12 |
ES2659424T3 (es) | 2018-03-15 |
BR112016016880A2 (pt) | 2017-10-03 |
IL246761A0 (en) | 2016-08-31 |
US10238656B2 (en) | 2019-03-26 |
EP3110444A1 (en) | 2017-01-04 |
AU2015223359A1 (en) | 2016-08-11 |
JP2016521262A (ja) | 2016-07-21 |
KR20160111001A (ko) | 2016-09-23 |
EP3110444B1 (en) | 2018-01-03 |
US20170173013A1 (en) | 2017-06-22 |
TW201542209A (zh) | 2015-11-16 |
TWI558399B (zh) | 2016-11-21 |
EA201691385A1 (ru) | 2016-12-30 |
SG11201606958YA (en) | 2016-09-29 |
WO2015130540A1 (en) | 2015-09-03 |
AP2016009402A0 (en) | 2016-08-31 |
CA2936558A1 (en) | 2015-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016011045A (es) | Terapia de combinacion para cancer. | |
AU2018201942B2 (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
MY202377A (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) | |
MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
PH12015502780B1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
MY179392A (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
MX2018001802A (es) | Metodos para el tratamiento del cancer de pancreas metastasico con el uso de terapias de combinacion que comprenden irinotecan liposomal y oxaliplatino. | |
MY186977A (en) | Tetrasubstituted alkene compounds and their use | |
MY191040A (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
SG10201902598VA (en) | Peptidomimetic macrocycles and formulations thereof | |
MX2016011295A (es) | Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2. | |
PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
EP3639829A4 (en) | USE OF ISOVALERYLSPIRAMYCIN I, II AND / OR III IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT AND / OR PREVENTION OF A TUMOR, AND A MEDICINAL PRODUCT | |
NZ745187A (en) | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
PH12015502564B1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
MX2015015601A (es) | Metodo para el tratamiento de cancer pulmonar por vacunacion con el lipopeptido mucina 1 (muc-1). | |
BR112013019080A2 (pt) | métodos para o tratamento do câncer, do nsclc e do câncer colorretal em um paciente humano e artigo de manufatura | |
EP3735261A4 (en) | GROWTH FACTOR TGFSS1 OR TGFSS2 OR TGFSS3 FOR USE IN ANTI-CANCER THERAPY FOR PATIENTS WITH TUMORS IN WHICH AT LEAST PART OF THE CELLS EXPRESS EGFRVIII | |
UA98544U (uk) | Спосіб лікування ендогенної інтоксикації у хворих на хронічне обструктивне захворювання легень | |
NZ725567A (en) | R-spondin translocations and methods using the same | |
UA93647U (uk) | Спосіб лікування латентної ішемічної хвороби серця у хворих на бронхіальну астму |